Reference values and biological determinants for cardiac myosin-binding protein C (cMyC) concentrations
Reference values and biological determinants
Abstract
Background: Cardiac myosin-binding protein C (cMyC) is a novel cardio-specific biomarker of potential diagnostic and prognostic value for cardiovascular events. The aim of this study is to determine reference values for cMyC and to identify biological determinants of its concentration.
Methods: A population of 488 presumably healthy adults was enrolled to define biological determinants which affect cMyC concentrations in serum. Concentrations of cMyC were assessed using enzyme-linked immunosorbent assays from commercially available kits. Eligibility for inclusion in this study evaluated anthropometric, demographic and laboratory measurements in all subjects. After applying strict inclusion criteria, a reference population (n=150) was defined and used for the determination of reference values. Reference values were derived using a robust method.
Results: The distribution of cMyC concentrations in the reference population was non-parametric, right-skewed, with only 2 subjects having concentrations lower than the limit of detection. Female gender was the only independent determinant of higher cMyC concentrations in the presumably healthy population. There were no significant relationships between cMyC and other investigated parameters in the reference population. The overall upper reference limit (URL) set at 99th percentile for cMyC concentration was 42.29 ng/mL and did not differ between women and men (42.52 vs. 42.35 ng/mL).
Conclusions: This study successfully established reference values for the assessed cMyC assay and investigated its biological determinants. Despite the impact of female gender on cMyC concentrations in the presumably healthy population, we did not detect sex-dependent differences in the cMyC 99th URL and we therefore recommend the use of a single 99th URL for adults.
References
[2] Kaier TE, Alaour B, Marber M. Cardiac Myosin-Binding Protein C—From Bench to Improved Diagnosis of Acute Myocardial Infarction. Cardiovasc Drugs Ther 2019; 33(2): 221–30.
[3] Offer G, Moos C, Starr R. A new protein of the thick filaments of vertebrate skeletal myofibrils. Extraction, purification and characterization. J Mol Biol 1973; 74(4): 653–76.
[4] Tong CW, Nair NA, Doersch KM, Liu Y, Rosas PC. Cardiac myosin-binding protein-C is a critical mediator of diastolic function. Pflugers Arch Eur J Physiol 2014; 466(3): 451–7.
[5] Flashman E, Redwood C, Moolman-Smook J, Watkins H. Cardiac myosin binding protein C: Its role in physiology and disease. Circ Res 2004; 94(10): 1279–89.
[6] Baker JO, Tyther R, Liebetrau C, Clark J, Sicard P, Kailey B, et al. Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol 2015; 110(3): 23.
[7] Sadayappan S. Cardiac myosin binding protein-C: A potential early-stage, cardiac-specific biomarker of ischemia-reperfusion injury. Biomark Med 2012; 6(1): 69–72.
[8] Krintus M, Koziński M, Boudry P, Lackner K, Lefèvre G, Lennartz L, et al. Defining normality in a European multinational cohort: Critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. Int J Cardiol 2015; 187: 256–63.
[9] Krintus M, Kozinski M, Fabiszak T, Kubica J, Panteghini M, Sypniewska G. Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clin Biochem 2017; 50(10-11): 599–604.
[10] Krintus M, Kozinski M, Braga F, Kubica J, Sypniewska G, Panteghini M. Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clin Chem Lab Med 2018; 56(7): 1161–8.
[11] Krintus M, Braga F, Kozinski M, Borille S, Kubica J, Sypniewska G, et al. A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. Clin Chem Lab Med 2019; 57(7): 1035–43.
[12] Krintus M, Kozinski M, Boudry P, Capell NE, Köller U, Lackner K, et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin i immunoassay. Clin Chem Lab Med 2014; 52(11): 1657–65.
[13] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599–726.
[14] Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107(3): 499–511.
[15] Panteghini M, John WG. Implementation of haemoglobin A1c results traceable to the IFCC reference system: The way forward. Clin Chem Lab Med 2007; 45(8): 942–4.
[16] Stevens PE, Levin A. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158(11): 825–30.
[17] CLSI. Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; approved guideline. CLSI document EP28A3c, Wayne (PA) Clinical and Laboratory Standards Institute, 2010.
[18] Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971; 17(4): 275–84.
[19] Marjot J, Liebetrau C, Goodson RJ, Kaier T, Weber E, Heseltine P, et al. The development and application of a high-sensitivity immunoassay for cardiac myosin-binding protein C. Transl Res 2016;170: 17-25.e5.
[20] Collet JP, Thiele H, Barbato E, Bauersachs J, Dendale P, Edvardsen T, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42(14): 1289–367.
[21] Kaier TE, Alaour B, Marber M. Cardiac myosin-binding protein C: How a novel biomarker could transform chest pain triage. Biomark Med 2018; 12(8): 823–6.
[22] Kaier TE, Twerenbold R, Puelacher C, Marjot J, Imambaccus N, Boeddinghaus J, et al. Direct Comparison of Cardiac Myosin-Binding Protein C with Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction. Circulation 2017; 136(16): 1495–508.
[23] Kong N, Chua RFM, Besser SA, Heelan L, Nathan S, Spiegel TF, et al. A retrospective analysis of high sensitivity cardiac troponin-T ranges in non-myocardial infarction emergency department visits. BMC Cardiovasc Disord 2021; 21(1): 1–8.
[24] Wu W, Li DX, Wang Q, Xu Y, Cui YJ. Relationship between high-sensitivity cardiac troponin T and the prognosis of elderly inpatients with non-acute coronary syndromes. Clin Interv Aging 2018;13:1091–8.
[25] Welsh P, Preiss D, Shah ASV, Mcallister D, Briggs A, Boachie C, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clin Chem 2018; 64(11): 1607–16.
[26] Tong CW, Dusio GF, Govindan S, Johnson DW, Kidwell DT, De La Rosa LM, et al. Usefulness of Released Cardiac Myosin Binding Protein-C as a Predictor of Cardiovascular Events. Am J Cardiol 2017; 120(9): 1501–7.
[27] Govindan S, Mcelligott A, Muthusamy S, Nair N. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. J Mol Cell Cardiol 2013; 52(1): 154–64.
[28] Kaier TE, Anand A, Shah AS, Mills NL, Marber M. Temporal Relationship between Cardiac Myosin-Binding Protein C and Cardiac Troponin I in Type 1 Myocardial Infarction. Clin Chem 2016; 62(8): 1153–5.
[29] Kuster DWD, Barefield D, Govindan S, Sadayappan S. A sensitive and specific quantitation method for determination of serum cardiac myosin binding protein-C by electrochemiluminescence immunoassay. J Vis Exp 2013; 78: 1–8.
[30] El Amrousy D, Hodeib H, Suliman G, Hablas N, Salama ER, Esam A. Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure. Pediatr Cardiol 2017; 38(2): 418–24.
[31] Khatab AA, El-Gazzar BA, Rizk MS, Abdel Ghani MGF. Value of plasma levels of cardiac myosin-binding protein C as a diagnostic and prognostic biomarker in heart failure. Menoufia Med J 2021; 34(1): 221.
[32] Alaour B, Omland T, Torsvik J, Kaier TE, Sylte MS, Strand H, et al. Biological variation of cardiac myosin-binding protein C in healthy individuals. Clin Chem Lab Med 2021; 60(4): 576–83.
[33] Hickman PE, Badrick T, Wilson SR, McGill D. Reporting of cardiac troponin - problems with the 99th population percentile. Clin Chim Acta 2007; 381(2): 182–3.
Copyright (c) 2023 Magdalena Krintus, Marek Kozinski, Sylwester M. Kloska, Katarzyna Bergmann, Aneta Mankowska-Cyl, Joanna Siodmiak, Grazyna Sypniewska
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.